Single Site, Phase II, Double Blind, Randomized, Placebo Controlled Study of the Effect of Dutasteride (Avodart) 0.5mg on the Volume and Characteristics of Prostate Cancer, as Assessed by Multifunctional Magnetic Resonance Imaging (MRI) in a Low Risk Prostate Cancer Population. (MAPPED TRIAL).

Next Previous
Trial Profile

Single Site, Phase II, Double Blind, Randomized, Placebo Controlled Study of the Effect of Dutasteride (Avodart) 0.5mg on the Volume and Characteristics of Prostate Cancer, as Assessed by Multifunctional Magnetic Resonance Imaging (MRI) in a Low Risk Prostate Cancer Population. (MAPPED TRIAL).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Dutasteride (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms MAPPED

    • Most Recent Events

    • 01 Jan 2013 Study design published in Contemporary Clinical Trials.
    • 03 Feb 2012 United Kingdom Clinical Research Network reports accrual date changed from 102% to 133%.
    • 03 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top